Longeveron (NASDAQ:LGVN) Stock Moved Up to “Hold” by Wall Street Zen

Longeveron (NASDAQ:LGVN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings downgraded Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $80.00.

Longeveron Stock Performance

NASDAQ:LGVN opened at $1.67 on Friday. Longeveron has a 52 week low of $1.31 and a 52 week high of $12.30. The firm has a market cap of $5.33 million, a price-to-earnings ratio of -0.17 and a beta of -0.19. The firm’s 50-day simple moving average is $3.90 and its 200 day simple moving average is $6.61.

Longeveron (NASDAQ:LGVN) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.75) by $1.56. Longeveron had a negative net margin of 1,977.59% and a negative return on equity of 223.19%. The firm had revenue of $0.29 million during the quarter, compared to the consensus estimate of $0.33 million. Sell-side analysts anticipate that Longeveron will post -7.20 EPS for the current year.

Institutional Investors Weigh In On Longeveron

An institutional investor recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC acquired a new stake in Longeveron Inc. (NASDAQ:LGVN) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned about 0.86% of Longeveron as of its most recent filing with the SEC. 10.01% of the stock is owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes.

Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.